Targeting PD-1H (VISTA) to Fight AML Immunosuppression
Official title: Targeting the PD-1H (VISTA) Pathway to Overcome Immunosuppression in Acute Myeloid Leukemia
Funded at Ohio State University · NIH-11394654 · Data updated 2026-11-12
A patient-focused look at a new approach that blocks PD-1H (VISTA) to help the immune system fight acute myeloid leukemia.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | August 20, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $425,038 |
| NIH project number | 5R37CA296259-02 |
| Project ID | NIH-11394654 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with acute myeloid leukemia or those at high risk of AML progression who may benefit from future immunotherapy trials targeting PD-1H (VISTA).
✕Less likely to help
Patients with AML who do not respond to immunotherapies or those unable to participate in translational trials may not benefit.
What this research studies
This project aims to understand how blocking PD-1H (VISTA) could lift the immune system’s suppression in AML so immune cells can attack leukemia. Researchers will study how PD-1H changes myeloid cells and T cell interactions in mouse models and with advanced cell profiling. The work will use myeloid-specific PD-1H knockout mice and single-cell analyses to map immune pathways driving AML progression. If these mechanisms are clarified, this could point to a novel, targeted immunotherapy for AML patients who currently have limited options.
Why it matters
Potential benefit: If successful, this research could lead to a new immunotherapy approach for AML that enhances immune attack on leukemia cells.
How similar studies have gone: Early data in AML models show PD-1H promotes immune suppression and faster disease, supporting further exploration of this target.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Han, Xue — Ohio State University
- Study coordinator: Han, Xue
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.